Chelsea Fertility NYC – FDA 483, Oct 11, 2022
An FDA inspection of Chelsea Fertility NYC, a reproductive human tissue establishment, revealed critical deficiencies in donor screening and record-keeping. The firm failed to adequately screen oocyte donors for communicable disease risks, including West Nile Virus and Creutzfeldt-Jakob disease, and improperly deemed an ineligible donor as eligible despite positive infectious disease markers. Additionally, the facility lacked established procedures for donor screening and maintained inaccurate or illegible donor eligibility records.
ID · 64326732-16aa-4fc6-b45f-c76f0c6592ac
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.